<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27112" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Phenobarbital</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lewis</surname>
            <given-names>Cassaundra B.</given-names>
          </name>
          <aff>Ross University SOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adams</surname>
            <given-names>Ninos</given-names>
          </name>
          <aff>Kern Medical</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Cassaundra Lewis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ninos Adams declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27112.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Phenobarbital is a member of the barbiturate drug class that holds versatile therapeutic applications. This drug is effective in anti-seizure management, treatment for status epilepticus, and insomnia; it also plays a pivotal role in addressing benzodiazepine and alcohol withdrawal.&#x000a0;This mechanism&#x000a0;involves&#x000a0;interaction with GABA-A receptor subunits, facilitating the sustained opening of chloride ion gates and a continuous influx of ions into neuronal cells. By elongating the opening duration of chloride channels, phenobarbital induces a depression in the central nervous system.&#x000a0;The resultant hyperpolarization of the cell membrane elevates the action potential threshold, rendering phenobarbital an effective solution for seizure treatment. In the event of a phenobarbital overdose, a critical situation demanding coordinated efforts from the interprofessional team, this educational session meticulously examines its indications, mechanism of action, toxicity, contraindications, administration, adverse effects, and monitoring. The aim is to equip the interprofessional team with comprehensive insights for adeptly&#x000a0;managing&#x000a0;a phenobarbital overdose.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for phenobarbital therapy based on patient-specific factors and clinical guidelines.</p></list-item><list-item><p>Screen patients for contraindications and potential drug interactions before initiating phenobarbital therapy.</p></list-item><list-item><p>Implement appropriate dosing regimens and administration techniques for phenobarbital, considering age, weight, and underlying medical conditions.</p></list-item><list-item><p>Develop collaboration with other healthcare professionals, such as pharmacists and specialists, to ensure coordinated and comprehensive care for patients receiving phenobarbital therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27112&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27112">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27112.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Phenobarbital is a sedative-hypnotic agent&#x000a0;belonging to the barbiturates class of drugs. Phenobarbital has multiple clinical uses that include anti-seizure management.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref> Phenobarbital is also recommended as an&#x000a0;agent to treat status epilepticus.<xref ref-type="bibr" rid="article-27112.r2">[2]</xref>&#x000a0;</p>
        <p>A study in China&#x000a0;compared valproic acid to phenobarbital to treat status epilepticus. Results showed that intravenous phenobarbital had better clinical outcomes in the study population&#x000a0;than valproic acid.<xref ref-type="bibr" rid="article-27112.r3">[3]</xref>&#x000a0;Although proven&#x000a0;effective for status epilepticus,&#x000a0;phenobarbital&#x000a0;has been&#x000a0;replaced with other drugs with less harmful side effects.<xref ref-type="bibr" rid="article-27112.r4">[4]</xref><xref ref-type="bibr" rid="article-27112.r2">[2]</xref>&#x000a0;</p>
        <p>Phenobarbital can also&#x000a0;be used&#x000a0;to&#x000a0;manage insomnia and apprehensiveness, although addiction is a point of concern when using phenobarbital for insomnia. This drug is also useful for&#x000a0;benzodiazepine and alcohol withdrawal&#x000a0;treatment&#x000a0;due to its anti-seizure properties and sedative effect. The syndrome resulting from alcohol withdrawal has a better clinical outcome&#x000a0;when treated with benzodiazepines, according&#x000a0;to significant evidence-based studies.<xref ref-type="bibr" rid="article-27112.r5">[5]</xref><xref ref-type="bibr" rid="article-27112.r6">[6]</xref>&#x000a0;</p>
        <p>Long-acting agents such as phenobarbital are not the preferred option for surgical induction; short-acting barbiturates are commonly used for this indication.<xref ref-type="bibr" rid="article-27112.r7">[7]</xref>&#x000a0;Phenobarbital reduces intracranial pressure by suppressing cerebral metabolism in severe brain injury management. Still, phenobarbital's adverse effect of hypotension negatively impacts the brain's oxygen supply, thus offsetting any clinical benefit.<xref ref-type="bibr" rid="article-27112.r8">[8]</xref></p>
      </sec>
      <sec id="article-27112.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Phenobarbital increases the&#x000a0;duration of&#x000a0;time chloride channels are open, depressing&#x000a0;the central nervous system. This action occurs by acting on GABA-A receptor subunits. When phenobarbital binds to these receptors, the chloride ion gates open and stay open, allowing a steady flow&#x000a0;of these ions into neuronal cells.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref>&#x000a0;This action&#x000a0;hyperpolarizes the cell membrane, increasing the action potential threshold.&#x000a0;This increase in action potential is why this drug is effective in treating&#x000a0;seizures.&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Rapid and complete absorption occurs after oral or IV administration.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref>&#x000a0;The time of peak plasma concentration ranges from&#x000a0;30 minutes to 1&#x000a0;hour for oral formulations and is around 5 minutes for IV injection.</p>
        <p><bold>Distribution:</bold> Rapidly distributed to all tissues and fluids.</p>
        <p><bold>Metabolism:</bold> Metabolized primarily via acetylation in the liver (hepatic microsomal enzyme system).<xref ref-type="bibr" rid="article-27112.r1">[1]</xref></p>
        <p><bold>Elimination:</bold> About 25% to 50% of the unchanged drug is excreted in the urine.&#x000a0;Remember that clearance rates vary with patients and their specific presentations. For instance,&#x000a0;patients who are terminally ill with cancer and on phenobarbital therapy may need dose adjustments due to reduced clearance of this drug.<xref ref-type="bibr" rid="article-27112.r9">[9]</xref></p>
      </sec>
      <sec id="article-27112.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Phenobarbital administration is via a variety of routes.<xref ref-type="bibr" rid="article-27112.r10">[10]</xref> These include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Oral Elixir:</bold>&#x000a0;20 mg/5 mL</p>
          </list-item>
          <list-item>
            <p><bold>Oral Tablets:</bold>&#x000a0;15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg, 100 mg</p>
          </list-item>
          <list-item>
            <p><bold>Intramuscular (IM)/Intravenous (IV) Solution:</bold> 65 mg/mL, 130 mg/mL&#x000a0;</p>
          </list-item>
        </list>
        <p>Phenobarbital&#x000a0;should only be given&#x000a0;intravenously for emergency cases. If possible, other routes of administration&#x000a0;should be accessed first. When given IV, check for any indurations. Studies have shown that an induration at a&#x000a0;site of infusion results in a decreased bioavailability of phenobarbital.<xref ref-type="bibr" rid="article-27112.r11">[11]</xref>&#x000a0;Another study demonstrated the effectiveness of the rectal administration of phenobarbital, with a relative bioavailability reaching 90%.<xref ref-type="bibr" rid="article-27112.r12">[12]</xref>&#x000a0;</p>
        <p>Patients can experience withdrawal symptoms if they stop taking the drug abruptly, so tapering off it is recommended. As per current guidelines from the American Epilepsy Society, generally, phenobarbital is given IV at 15 mg/kg in adult patients with status epilepticus.<xref ref-type="bibr" rid="article-27112.r13">[13]</xref></p>
        <p>
<bold>Specific Patient Populations&#x000a0;</bold>
</p>
        <p><bold>Hepatic impairment: </bold>The manufacturer label provides no dose adjustment guidance for patients with hepatic impairment. However, phenobarbital is a potent inducer of cytochrome P450 enzymes, leading to interactions with other drugs by increasing their clearance.&#x000a0;Therefore, phenobarbital should be&#x000a0;used cautiously in patients with severe hepatic impairment.</p>
        <p><bold>Renal impairment:</bold> The manufacturer label does not provide dose adjustment guidance<bold>&#x000a0;</bold>for patients with&#x000a0;renal impairment. However, approximately 25% to 50% of phenobarbital is eliminated in the urine, so the drug should be used cautiously in patients with severe renal impairment.&#x000a0;</p>
        <p><bold>Pregnancy considerations: </bold>Phenobarbital&#x000a0;is considered a pregnancy Category D medicine. Barbiturates are reported to cause fetal damage when administered to a pregnant female patient. No systematic and well-controlled studies have been reported for pregnant women. Maternal administration of barbiturates&#x000a0;reportedly has&#x000a0;a higher-than-expected incidence of fetal abnormality in retrospective, case-controlled studies.</p>
        <p>Barbiturates, including phenobarbital, readily cross the placental barrier and are distributed throughout fetal tissues, and high concentrations are detected in the placenta, brain, and fetal liver. Withdrawal symptoms can occur in infants born to females who are administered barbiturates throughout the last trimester of pregnancy. If phenobarbital is administered during pregnancy or the patient gets pregnant while taking the drug. The patient should be informed and counseled about the potential hazard to the fetus. This drug should be used with caution only if needed during pregnancy.<xref ref-type="bibr" rid="article-27112.r14">[14]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>The manufacturer recommends caution for phenobarbital therapy in nursing mothers as the drug is present in breast milk. If infants' excessive drowsiness and poor weight gain are observed, limiting or discontinuing phenobarbital is also recommended.<xref ref-type="bibr" rid="article-27112.r15">[15]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Reports indicate phenobarbital is associated with cognitive deficits in&#x000a0;pediatric&#x000a0;therapy for complicated febrile seizures. Using the dose as per the manufacturer's label is recommended.</p>
        <p><bold>Older patients:&#x000a0;</bold>The safety and efficacy of phenobarbital are not systematically studied in&#x000a0;older patients. However, it is recommended to use the drug cautiously as it may cause excitement, depression, or confusion in some&#x000a0;older patients.</p>
      </sec>
      <sec id="article-27112.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Complications associated with phenobarbital use&#x000a0;include coma, impaired breathing effort, low blood pressure, incoordination, poor balance, and drowsiness.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref>&#x000a0;These adverse effects, stemming from phenobarbital usage, impact&#x000a0;older patients to a greater degree. Therefore, newer&#x000a0;antiepileptics (lamotrigine, levetiracetam)&#x000a0;are preferred as seizure treatment in this patient population.<xref ref-type="bibr" rid="article-27112.r16">[16]</xref>&#x000a0;</p>
        <p>When used long-term, adverse events of phenobarbital include irritability, loss of appetite, achiness in the bones, joints, or muscles, depression, and, rarely, liver damage.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref>&#x000a0;When taking barbiturates such as phenobarbital,&#x000a0;patients may&#x000a0;experience withdrawal symptoms if they stop taking the drug abruptly; tapering off the medication is necessary.</p>
        <p>In post-marketing surveillance of hospitalized patients using phenobarbital, the following adverse reactions have&#x000a0;been&#x000a0;reported:</p>
        <p><bold>Nervous system:</bold> Agitation, somnolence, confusion, CNS depression, hyperkinesia, ataxia,&#x000a0; nervousness, nightmares, psychiatric disturbance,&#x000a0; thinking abnormality, insomnia, anxiety, hallucinations, dizziness</p>
        <p><bold>Respiratory:</bold> Apnea, hypoventilation</p>
        <p><bold>Cardiovascular:</bold> Hypotension, bradycardia, syncope</p>
        <p><bold>Gastrointestinal:</bold> Nausea, vomiting, constipation</p>
        <p><bold>Dermatologic:</bold> Exfoliative dermatitis, toxic epidermic necrolysis,&#x000a0;Stevens-Johnson syndrome (rare)&#x000a0;</p>
        <p><bold>Others:</bold>&#x000a0;Headache; hypersensitivity reactions, including but not limited to angioedema and skin rashes, injection site reactions, fever, liver damage and megaloblastic anemia in chronic users</p>
      </sec>
      <sec id="article-27112.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Phenobarbital is contraindicated in patients with known barbiturate sensitivity. Barbiturates, including phenobarbital, are contraindicated in patients with a history of latent porphyria, liver impairment, and large doses in patients with nephritic syndrome. Phenobarbital should not be given to persons with a known history of addiction to sedative-hypnotic medicines. Injectable preparation should not be given via intraarterial or subcutaneous routes.</p>
        <p>Phenobarbital is a potent cytochrome P450 inducer, so careful consideration is necessary when given concurrently with other medications. For instance, a woman with epilepsy who takes oral contraceptive pills and phenobarbital at the same time must be fully aware of the possible&#x000a0;interaction between the medications. Phenobarbital is known to induce the liver's cytochrome p450 enzymes, speeding up the metabolism of estrogens and progestins. Thus, a woman taking both antiepileptic medication and oral contraceptive pills&#x000a0;may experience an unexpected pregnancy due to the decreased efficacy of her oral contraceptive pills.<xref ref-type="bibr" rid="article-27112.r17">[17]</xref>&#x000a0;Patients taking warfarin must have close monitoring of INR due to drug interactions.</p>
        <p>Patients with underlying obstructive lung disease will have an increased risk of complications.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref>&#x000a0;The&#x000a0;depression of the respiratory system associated with barbiturate toxicity compounded with an already compromised respiratory system can contribute&#x000a0;to complications.&#x000a0;Research has&#x000a0;also&#x000a0;found that the drug interaction from combined oral theophylline medication&#x000a0;and phenobarbital negatively impacted theophylline blood levels compared to plain oral theophylline pills.&#x000a0;Phenobarbital has shown a capacity to decrease levels of steroids and theophylline via the cytochrome p450 liver metabolism system.<xref ref-type="bibr" rid="article-27112.r18">[18]</xref>&#x000a0;Therefore, patients receiving combined oral therapy for their lung condition may experience issues with&#x000a0;subtherapeutic blood levels of corticosteroids or theophylline.&#x000a0;</p>
        <p>Abstinence&#x000a0;from alcohol while taking barbiturates is crucial because of the danger of severe respiratory depression&#x000a0;when both drugs are in the patient's system. When taken simultaneously, both drugs' individual&#x000a0;effects&#x000a0;on&#x000a0;GABA-A are additive, potentially resulting in&#x000a0;a life-threatening scenario.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref></p>
      </sec>
      <sec id="article-27112.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Phenobarbital's effective dosage is between 10 to 40 &#x003bc;g/mL. Once blood levels exceed&#x000a0;40 &#x003bc;g/mL, the patient is in a lethal range and at substantial risk.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref></p>
      </sec>
      <sec id="article-27112.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Barbiturate toxicity is noticeable at 1 g orally, although this varies&#x000a0;depending on the individual. Doses above 2 g can result in death, but&#x000a0;the deadly&#x000a0;dose usually is&#x000a0;between 40&#x000a0;and 80 &#x003bc;g/mL.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Toxicity from barbiturates varies, but common symptoms include&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cognitive impairment</p>
          </list-item>
          <list-item>
            <p>Decreased heart rate</p>
          </list-item>
          <list-item>
            <p>Incoordination</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Muscle weakness</p>
          </list-item>
          <list-item>
            <p>Polydipsia</p>
          </list-item>
          <list-item>
            <p>Below-normal urine output</p>
          </list-item>
          <list-item>
            <p>Decreased body temperature</p>
          </list-item>
          <list-item>
            <p>Mydriasis</p>
          </list-item>
        </list>
        <p>Deaths have occurred due to respiratory depression, hypotension, and coma.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Phenobarbital overdose is a healthcare emergency and requires teamwork from the entire healthcare spectrum to help the patient.&#x000a0;The healthcare team must implement the management of cardiac and respiratory status quickly.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref><xref ref-type="bibr" rid="article-27112.r19">[19]</xref>&#x000a0;Alkalinizing the urine can help eliminate the drug, but if prior interventions fail to advance patients in a positive direction,&#x000a0;hemodialysis or hemoperfusion can expedite drug clearance.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref><xref ref-type="bibr" rid="article-27112.r20">[20]</xref><xref ref-type="bibr" rid="article-27112.r21">[21]</xref>&#x000a0;</p>
        <p>Hemoperfusion&#x000a0;was&#x000a0;thought to be&#x000a0;more effective in phenobarbital overdose&#x000a0;due to increased protein binding; however, a case of severe phenobarbital intoxication treated with high-efficiency dialyzers and increased rates of blood flow showed that hemodialysis is the better option for drug clearance in compromised patients. The patient experienced a positive clinical outcome after phenobarbital levels dropped rapidly.<xref ref-type="bibr" rid="article-27112.r20">[20]</xref></p>
        <p>
<bold>Recommendations</bold>
</p>
        <p>Treatment of phenobarbital toxicity is supportive, comprising&#x000a0;maintenance of airway function (through endotracheal intubation and mechanical ventilation), correction of bradycardia, and hypotension (with IV fluids and vasopressors, if necessary).<xref ref-type="bibr" rid="article-27112.r18">[18]</xref>&#x000a0;</p>
        <p>After properly evaluating and correcting the patient's airway, breathing, and circulation, removing the drug from the body is&#x000a0;imperative; this can occur via gastric irrigation,&#x000a0;forced alkaline diuresis,&#x000a0;or dialysis.<xref ref-type="bibr" rid="article-27112.r20">[20]</xref>&#x000a0;A specific treatment does not currently exist.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref></p>
      </sec>
      <sec id="article-27112.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Phenobarbital is a class IV control substance, and it is used&#x000a0;for&#x000a0;its&#x000a0;sedative and anti-seizure properties in patients with status epileptics and alcohol withdrawal management. However, it is no longer a first-line agent. Phenobarbital is known for being highly addictive and was historically a common agent of choice for suicide attempts.<xref ref-type="bibr" rid="article-27112.r19">[19]</xref>&#x000a0;Phenobarbital is a drug that&#x000a0;poses an emergent&#x000a0;situation for the interprofessional healthcare&#x000a0;team when a patient&#x000a0;arrives&#x000a0;after an attempted or accidental overdose.</p>
        <p>Although restrictions on access to barbiturates have&#x000a0;led to a decline in&#x000a0;the number of overdoses, expeditiously assessing and treating patients with a phenobarbital overdose is still crucial.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref>&#x000a0;In case of a suspected drug overdose, the healthcare team must&#x000a0;evaluate the patient's vitals and ensure optimal respiratory effort. If&#x000a0;respiration is compromised, precautions for respiratory support must be&#x000a0;implemented (endotracheal intubation or mechanical ventilation). As a next step, urine or blood toxicology is necessary&#x000a0;to confirm the suspected diagnosis.</p>
        <p>While in recovery, patients require counsel&#x000a0;about barbiturates and proper&#x000a0;use.<xref ref-type="bibr" rid="article-27112.r1">[1]</xref>&#x000a0;This educational opportunity and a psychiatric evaluation are pertinent for the patient. Regarding preventing future overdoses, an interprofessional effort among patients' healthcare providers is necessary to&#x000a0;ensure that the patient is not prescribed many pills at once. Prescribers can also evaluate whether the patient can be switched to an alternative medication.</p>
        <p>A cohort study showed that subjects who purposely overdosed on barbiturates showed an increased risk of an adverse ICU course. If clinicians judiciously prescribe&#x000a0;barbiturates, the patient is less likely to overdose and thus less likely to&#x000a0;have an unfavorable hospital course.<xref ref-type="bibr" rid="article-27112.r22">[22]</xref>&#x000a0;Nurses should check for vitals and any adverse reactions at all visits; they must be aware of the signs of toxicity or misuse to alert the prescriber. Pharmacists should verify phenobarbital's dose, duration, and drug interactions and inform prescribers of any concerns.</p>
        <p>In summary, the management of therapy with phenobarbital is the responsibility of the interprofessional healthcare team, including clinicians, specialists, pharmacists, and mental health practitioners, operating as a cohesive unit to optimize treatment outcomes and prevent mortality and morbidity from phenobarbital misuse.&#x000a0;</p>
      </sec>
      <sec id="article-27112.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27112&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27112">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27112/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27112">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27112.s11">
        <title>References</title>
        <ref id="article-27112.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Suddock</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Cain</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <chapter-title>Barbiturate Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29763050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falco-Walter</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Established Status Epilepticus.</article-title>
            <source>J Clin Med</source>
            <year>2016</year>
            <month>Apr</month>
            <day>25</day>
            <volume>5</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">27120626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China.</article-title>
            <source>CNS Drugs</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>12</issue>
            <fpage>1201</fpage>
            <page-range>1201-1207</page-range>
            <pub-id pub-id-type="pmid">27878767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hocker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Britton</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Parenteral phenobarbital in status epilepticus revisited: Mayo Clinic experience.</article-title>
            <source>Epilepsia</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>59 Suppl 2</volume>
            <fpage>193</fpage>
            <page-range>193-197</page-range>
            <pub-id pub-id-type="pmid">30159873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sachdeva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Choudhary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>VE01</fpage>
            <page-range>VE01-VE07</page-range>
            <pub-id pub-id-type="pmid">26500991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammond</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kane-Gill</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Patient Outcomes Associated With Phenobarbital Use With or Without Benzodiazepines for Alcohol Withdrawal Syndrome: A Systematic Review.</article-title>
            <source>Hosp Pharm</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>607</fpage>
            <page-range>607-616</page-range>
            <pub-id pub-id-type="pmid">29276297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dumps</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Halbeck</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bolkenius</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Drugs for intravenous induction of anesthesia: barbiturates].</article-title>
            <source>Anaesthesist</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>67</volume>
            <issue>7</issue>
            <fpage>535</fpage>
            <page-range>535-552</page-range>
            <pub-id pub-id-type="pmid">29744526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sydenham</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Barbiturates for acute traumatic brain injury.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Dec</month>
            <day>12</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD000033</fpage>
            <pub-id pub-id-type="pmid">23235573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Echizen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of Life.</article-title>
            <source>Eur J Drug Metab Pharmacokinet</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-82</page-range>
            <pub-id pub-id-type="pmid">30027304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilensky</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Friel</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Comfort</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Kaluzny</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Kinetics of phenobarbital in normal subjects and epileptic patients.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1982</year>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-92</page-range>
            <pub-id pub-id-type="pmid">7128675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Echizen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Akabane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Orii</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Induration at Injection or Infusion Site May Reduce Bioavailability of Parenteral Phenobarbital Administration.</article-title>
            <source>Ther Drug Monit</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-302</page-range>
            <pub-id pub-id-type="pmid">28328763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graves</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Kriel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Jones-Saete</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ehresman</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Relative bioavailability of rectally administered phenobarbital sodium parenteral solution.</article-title>
            <source>DICP</source>
            <year>1989</year>
            <season>Jul-Aug</season>
            <volume>23</volume>
            <issue>7-8</issue>
            <fpage>565</fpage>
            <page-range>565-8</page-range>
            <pub-id pub-id-type="pmid">2763578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bare</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Garrity</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jagoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pellock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.</article-title>
            <source>Epilepsy Curr</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-61</page-range>
            <pub-id pub-id-type="pmid">26900382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czeizel</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Dud&#x000e1;s</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>B&#x000e1;nhidy</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Interpretation of controversial teratogenic findings of drugs such as phenobarbital.</article-title>
            <source>ISRN Obstet Gynecol</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>719675</fpage>
            <pub-id pub-id-type="pmid">21904684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Phenobarbital</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Hakimian</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy.</article-title>
            <source>Drugs Aging</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>687</fpage>
            <page-range>687-698</page-range>
            <pub-id pub-id-type="pmid">30003428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabers</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic interactions between contraceptives and antiepileptic drugs.</article-title>
            <source>Seizure</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-4</page-range>
            <pub-id pub-id-type="pmid">18206393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sayer</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Hazards of barbiturates in the treatment of asthma, bronchitis, and obstructive pulmonary disease.</article-title>
            <source>West J Med</source>
            <year>1975</year>
            <month>Jun</month>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>492</fpage>
            <pub-id pub-id-type="pmid">1136437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindberg</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lindberg</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Acute phenobarbital intoxication.</article-title>
            <source>South Med J</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>85</volume>
            <issue>8</issue>
            <fpage>803</fpage>
            <page-range>803-7</page-range>
            <pub-id pub-id-type="pmid">1502622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmer</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>640</fpage>
            <page-range>640-3</page-range>
            <pub-id pub-id-type="pmid">10977799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Enhanced elimination in acute barbiturate poisoning - a systematic review.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-12</page-range>
            <pub-id pub-id-type="pmid">21288146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27112.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ichikura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okumura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Associations of Adverse Clinical Course and Ingested Substances among Patients with Deliberate Drug Poisoning: A Cohort Study from an Intensive Care Unit in Japan.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>e0161996</fpage>
            <pub-id pub-id-type="pmid">27560966</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
